Advertisement
General Clark is one of the country's most distinguished retired militaryofficers and a respected international voice in public affairs and diplomacy.He served as NATO Supreme Allied Commander from 1997 to 2000 and commandedtroops in the campaign to end the Kosovo War, and he played a pivotal role innegotiating the Dayton Peace Accords to end the war in Bosnia.
Advertisement
"I am truly impressed by the private/public partnerships that Immtech hascreated as part of its effective business model to develop new treatments forglobal diseases," said General Clark. "I look forward to working closely withImmtech's leadership as the Company advances Immtech's promising drugpipeline."
General Clark served for 33 years with the United States Army, rising tothe rank of 4-star general. He is a recipient of the Silver Star, Bronze Star,and Purple Heart, along with honorary Knighthoods from the British and Dutchgovernments. He was also made a commander of the French Legion of Honor, andin 2000 he was awarded the Presidential Medal of Freedom, the nation's highestcivilian honor.
"We are honored to have General Clark join Immtech in this strategicadvisory role," said Eric L. Sorkin, Immtech's Chairman and Chief ExecutiveOfficer. "General Clark will enhance Immtech's strategic work withinternational companies, foundations and governments. Few people have a betterunderstanding of international cooperation, and we stand to benefit greatlyfrom General Clark's expertise."
General Clark graduated top of his class from the United States MilitaryAcademy at West Point, and he holds a Master's Degree from Oxford Universitywhere he was a Rhodes Scholar. He was a U.S. presidential candidate in the2004 election and is presently Chairman and CEO of Wesley K. Clark &Associates, a strategic advisory and consulting firm. He is also Chairman ofRodman and Renshaw, a New York based investment bank.
Immtech's first oral drug candidate, pafuramidine maleate, is currently intwo phase II clinical trials for treatment and prevention of malaria. Eachyear malaria kills over one million people. It is also a significant threat to125 million people who travel annually from developed countries to malariaendemic areas. Pafuramidine is also in two pivotal Phase III trials targetingthe treatment of Pneumocystis pneumonia (PCP), a severe form of fungalinfection in the lungs, and African sleeping sickness.
About Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc. is focused on developing and commercializingdrugs to treat infectious diseases. Immtech has advanced clinical programsthat include new treatments for Pneumocystis pneumonia (PCP), malaria, andtrypanosomiasis (African sleeping sickness), and a well defined, expandinglibrary of compounds targeting Hepatitis C, fungal infections, and bacterialinfections. Immtech holds exclusive worldwide licenses to certain patents,patent applications and technology for products derived from a proprietarypharmaceutical platform. For additional information, please go tohttp://www.immtechpharma.com.
"Safe Harbor" Statement under the Private Securities Reform Act of 1995:Statements in this press release regarding Immtech Pharmaceuticals, Inc.'sbusiness, including the future prospects for PCP, which are not historicalfacts are "forward- looking statements" that involve risks and uncertainties.Actual results could differ materially from these forward-looking statements.Factors that could cause or contribute to such differences include, but arenot limited to, those
